In a previous blog post, I took a look at Western blots in papers from the lab of Dr. Hoau-Yan Wang at City University of New York (CUNY), mostly related to Cassava Sciences (Nasdaq: $SAVA), its predecessor Pain Therapeutics INC, and its flagship Alzheimer’s Disease drug candidate Simufilam.
While those papers were mainly about the preclinical Simufilam data, here I will review a conference poster reporting on Phase 2 data obtained by Cassava Sciences.
Continue reading “Cassava Sciences: Of Posters and Spaghetti Plots”
A group of anonymous persons filed a Statement of Concern with the FDA regarding the integrity of research papers about Simufilam, an Alzheimer’s Disease treatment drug candidate developed by Cassava Sciences (Nasdaq: $SAVA). The petition raises concerns about Western blots and methodology. I took a look at the problematic photos included in the report, and agree with most of those concerns. I also found some additional problems.
Continue reading “Cassava Sciences: Of stocks and blots”
Last week, a new retrospective study from Tongji Hospital in Wuhan was published in Science China Life Sciences (a Springer Link journal). The study found 47% fatalities in critically ill #COVID19 patients that were given regular treatment, and only 19% fatalities in patients treated with low doses of hydroxychloroquine (HCQ).
These results sound amazing.
But I took a closer look. And I have lots of questions.
Continue reading “Low dose of hydroxychloroquine – but lots of questions”